The risk of ketoacidosis among patients without T2DM is very low; a meta-analysis of SGLT2 inhibitor clinical trials found only 1 event of ketoacidosis in such patients receiving an SGLT2 inhibitor during approximately 30,000 patient-years of follow-up.29 This evidence concerns the gene SLC5A2 and diabetes mellitus.